ValuEngine downgraded shares of C.R. Bard (NYSE:BCR) from a buy rating to a hold rating in a report published on Friday.

Other research analysts have also issued research reports about the company. Barclays lifted their price target on C.R. Bard from $245.00 to $337.00 and gave the stock an equal weight rating in a research report on Monday, November 6th. Jefferies Group reaffirmed a hold rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Cowen reaffirmed a hold rating and set a $317.00 price target on shares of C.R. Bard in a research report on Friday, November 3rd. Needham & Company LLC reaffirmed a hold rating on shares of C.R. Bard in a research report on Thursday, October 26th. Finally, BidaskClub lowered C.R. Bard from a hold rating to a sell rating in a research report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a strong buy rating to the company. C.R. Bard currently has a consensus rating of Hold and a consensus target price of $303.50.

C.R. Bard (BCR) traded up $0.12 on Friday, reaching $336.06. The company’s stock had a trading volume of 516,992 shares, compared to its average volume of 524,767. The firm has a market capitalization of $24,487.46, a price-to-earnings ratio of 29.01, a price-to-earnings-growth ratio of 2.57 and a beta of 0.53. C.R. Bard has a 52 week low of $206.71 and a 52 week high of $337.73. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.

C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping the consensus estimate of $2.96 by $0.06. The company had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The firm’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.64 earnings per share. sell-side analysts predict that C.R. Bard will post 11.89 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be paid a $0.26 dividend. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. C.R. Bard’s dividend payout ratio (DPR) is currently 13.70%.

In other C.R. Bard news, Director David M. Barrett sold 3,344 shares of C.R. Bard stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $327.31, for a total value of $1,094,524.64. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Sharon M. Luboff sold 30,252 shares of C.R. Bard stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $320.00, for a total value of $9,680,640.00. The disclosure for this sale can be found here. Insiders sold a total of 191,593 shares of company stock worth $62,655,513 over the last quarter. Company insiders own 0.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in BCR. Leucadia National Corp purchased a new stake in shares of C.R. Bard in the second quarter valued at approximately $13,184,000. Vivaldi Asset Management LLC purchased a new stake in shares of C.R. Bard in the second quarter valued at approximately $57,965,000. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of C.R. Bard by 12.3% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 16,951 shares of the medical instruments supplier’s stock valued at $5,358,000 after buying an additional 1,859 shares in the last quarter. Artemis Investment Management LLP boosted its stake in shares of C.R. Bard by 33.4% in the second quarter. Artemis Investment Management LLP now owns 41,313 shares of the medical instruments supplier’s stock valued at $13,068,000 after buying an additional 10,354 shares in the last quarter. Finally, Sirios Capital Management L P purchased a new stake in shares of C.R. Bard in the second quarter valued at approximately $71,393,000. Institutional investors own 79.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “C.R. Bard (BCR) Downgraded by ValuEngine to Hold” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/02/c-r-bard-bcr-downgraded-by-valuengine-to-hold.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.